AstraZeneca Says Its Likely to Run Fresh Global Vaccine Trial

The transcript discusses AstraZeneca's COVID-19 vaccine trials, focusing on the unexpected higher efficacy in a lower dose group. The company plans a global trial to ensure diverse data and address age cohort gaps. Approval is expected in Europe and the UK by year-end, but US approval may be slower due to additional trial requirements.

What concerns were raised regarding the age demographics in the vaccine trials?

What is the expected timeline for the vaccine approval in Europe according to Pascal Soriot?